US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
EP0766667A1
(en)
*
|
1994-06-20 |
1997-04-09 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
AU7361796A
(en)
*
|
1995-09-27 |
1997-04-17 |
Schering Corporation |
Stereoselective microbial reduction process
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
EP0766962A3
(en)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Treatment of atherosclerosis
|
AR004701A1
(es)
*
|
1995-10-31 |
1999-03-10 |
Schering Corp |
2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.
|
WO1997016424A1
(en)
*
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
AU1977997A
(en)
|
1996-02-23 |
1997-09-10 |
Eli Lilly And Company |
Non-peptidyl vasopressin v1a antagonists
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
ES2244238T3
(es)
*
|
1998-12-07 |
2005-12-01 |
Schering Corporation |
Proceso para la sintesis de azetidinonas.
|
DE69911058T2
(de)
*
|
1998-12-23 |
2004-06-03 |
G.D. Searle Llc, Chicago |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
DE69907960T2
(de)
|
1998-12-23 |
2004-02-26 |
G.D. Searle Llc, Chicago |
Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
|
AU776664B2
(en)
*
|
1998-12-23 |
2004-09-16 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
DE69904079T2
(de)
|
1998-12-23 |
2003-07-17 |
G.D. Searle Llc, Chicago |
Kombinationen von ileumgallensäuretransports inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
KR20010108046A
(ko)
|
1998-12-23 |
2001-12-07 |
윌리암스 로저 에이 |
심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및콜레스테릴 에스테르 운반 단백질 저해제의 조합물
|
WO2000038723A1
(en)
|
1998-12-23 |
2000-07-06 |
G.D. Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
|
ES2201822T3
(es)
*
|
1998-12-23 |
2004-03-16 |
G.D. Searle Llc |
Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
|
CN1249250C
(zh)
|
1999-04-05 |
2006-04-05 |
先灵公司 |
用于制备1-(4-氟苯基)-3(R)-[3(S)-羟基-3-(4-氟苯基)丙基]-4(S)-(4-羟苯基)-2-β丙内酰胺的立体选择性微生物还原反应
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
WO2001068096A2
(en)
*
|
2000-03-10 |
2001-09-20 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
AU2002227240A1
(en)
*
|
2000-10-30 |
2002-05-15 |
Schering Corporation |
Treatment and method using loratadine and montelukast
|
EP1593670B1
(en)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1510521A1
(en)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
EP1347987B1
(en)
*
|
2000-12-20 |
2004-10-13 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
NZ526593A
(en)
*
|
2000-12-21 |
2005-02-25 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
IL156552A0
(en)
*
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
WO2002058731A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
RS20100015A
(en)
*
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
DK1355644T3
(da)
*
|
2001-01-26 |
2006-10-23 |
Schering Corp |
Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
|
EP1911462A3
(en)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Compositions comprising a sterol absorption inhibitor
|
JP2004517916A
(ja)
*
|
2001-01-26 |
2004-06-17 |
シェーリング コーポレイション |
ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
AR035739A1
(es)
*
|
2001-01-26 |
2004-07-07 |
Schering Corp |
Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
KR20080067717A
(ko)
*
|
2001-01-26 |
2008-07-21 |
쉐링 코포레이션 |
스테롤 흡수 억제제와 혈액 조절제를 포함하는 혈관 질환의치료 또는 예방용 약제학적 조성물
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
TWI291957B
(en)
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
EP1373230B1
(en)
*
|
2001-03-28 |
2005-09-28 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DK1392287T3
(da)
*
|
2001-05-25 |
2007-03-19 |
Schering Corp |
Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
DE60216300T2
(de)
*
|
2001-09-21 |
2007-06-28 |
Schering Corp. |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
EP1859796A3
(en)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
CA2464685A1
(en)
*
|
2001-11-02 |
2003-05-15 |
G.D. Searle Llc |
Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
|
IL161741A0
(en)
*
|
2001-11-09 |
2005-11-20 |
Atherogenics Inc |
Methods of reversing and preventingcardiovascular pathologies
|
WO2003053359A2
(en)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
TW200303302A
(en)
*
|
2001-12-19 |
2003-09-01 |
Atherogenics Inc |
Chalcone derivatives and their use to treat diseases
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
AU2003207431A1
(en)
|
2002-01-17 |
2003-09-02 |
Pharmacia Corporation |
Novel alkyl/aryl hydroxy or keto thiepines.
|
AU2003217276A1
(en)
*
|
2002-02-28 |
2003-09-16 |
Eli Lilly And Company |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
EP1656368A4
(en)
*
|
2002-07-09 |
2009-08-26 |
Bristol Myers Squibb Co |
SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
CA2517573C
(en)
*
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
CA2517571C
(en)
*
|
2003-03-07 |
2011-07-05 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
WO2004081003A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
|
CN1805926A
(zh)
*
|
2003-05-05 |
2006-07-19 |
兰贝克赛实验室有限公司 |
二苯基氮杂环丁酮衍生物的反式异构体的制备方法
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
WO2004106299A2
(en)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives and their use as hmg-co inhibitors
|
WO2005000217A2
(en)
*
|
2003-06-06 |
2005-01-06 |
Merck & Co., Inc. |
Combination therapy for the treatment of dyslipidemia
|
AU2004259747B2
(en)
*
|
2003-07-24 |
2009-02-19 |
Merck Frosst Canada Ltd |
Diphenyl substituted Cycloalkanes, compositions containing such compounds and methods of use
|
WO2005009955A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
EP1522541A1
(en)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Novel hypocholesterolemic compounds
|
WO2005042692A2
(en)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
|
JP2007510659A
(ja)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
|
EP1918000A2
(en)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
US7320972B2
(en)
*
|
2003-11-10 |
2008-01-22 |
Microbia, Inc. |
4-Biarylyl-1-phenylazetidin-2-ones
|
WO2005049592A1
(en)
*
|
2003-11-24 |
2005-06-02 |
Hetero Drugs Limited |
A novel process for ezetimibe intermediate
|
EP1699759B1
(en)
*
|
2003-12-23 |
2010-10-20 |
AstraZeneca AB |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
CA2550373C
(en)
|
2003-12-23 |
2012-01-31 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compounds
|
WO2005069900A2
(en)
*
|
2004-01-16 |
2005-08-04 |
Merck & Co., Inc. |
Npc1l1 (npc3) and methods of identifying ligands thereof
|
CA2558766A1
(en)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
PT1756049E
(pt)
*
|
2004-05-21 |
2007-12-17 |
Sanofi Aventis Deutschland |
Processo para a preparação de derivados de 1,4-difenilazetidinona
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
WO2006026273A2
(en)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
AR050631A1
(es)
*
|
2004-09-09 |
2006-11-08 |
Novartis Ag |
Combinacion de compuestos organicos
|
MX2007003732A
(es)
*
|
2004-09-29 |
2007-04-23 |
Schering Corp |
Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
|
NZ555320A
(en)
|
2004-12-03 |
2010-11-26 |
Schering Corp |
Substituted piperazines as CB1 antagonists
|
JP2008523807A
(ja)
*
|
2004-12-15 |
2008-07-10 |
シェーリング コーポレイション |
コレステロール吸収インヒビターについての機能アッセイ
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
WO2006107936A1
(en)
*
|
2005-04-04 |
2006-10-12 |
Pontificia Universidad Catolica De Chile |
The use of ezetimibe in the prevention and treatment of cholesterol gallstones
|
TW200726746A
(en)
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
CN101212978A
(zh)
*
|
2005-05-09 |
2008-07-02 |
迈克罗比亚公司 |
有机金属苯基膦酸酯偶联剂
|
JP2008540557A
(ja)
*
|
2005-05-11 |
2008-11-20 |
マイクロビア インコーポレーテッド |
フェノール型4−ビフェニリルアゼチジン−2−オンの製造方法
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
EP1896135A2
(en)
*
|
2005-05-25 |
2008-03-12 |
Microbia, Inc. |
Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
|
AU2006259646A1
(en)
*
|
2005-06-15 |
2006-12-28 |
Merck Sharp & Dohme Corp. |
Anti-hypercholesterolemic compounds
|
US7635705B2
(en)
*
|
2005-06-20 |
2009-12-22 |
Schering Corporation |
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
US8013150B2
(en)
*
|
2005-06-22 |
2011-09-06 |
Msn Laboratories Ltd. |
Process for the preparation of ezetimibe
|
EP1741427A1
(en)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Pharmaceutical composition comprising simvastatin and ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
JP2008517951A
(ja)
*
|
2005-09-08 |
2008-05-29 |
テバ ファーマシューティカル インダストリーズ リミティド |
(3r,4s)−4−((4−ベンジルオキシ)フェニル)−1−(4−フルオロフェニル)−3−((s)−3−(4−フルオロフェニル)−3−ヒドロキシプロピル)−2−アゼチジノン、すなわちエゼチミベの合成のための中間体の調製方法
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
CN101291662A
(zh)
|
2005-10-21 |
2008-10-22 |
诺瓦提斯公司 |
肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合
|
WO2007054896A1
(en)
*
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
JP2009521452A
(ja)
*
|
2005-12-21 |
2009-06-04 |
シェーリング コーポレイション |
コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
|
ATE445596T1
(de)
*
|
2005-12-22 |
2009-10-15 |
Medichem Sa |
Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
|
WO2007084450A2
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
CN101384532B
(zh)
*
|
2006-02-16 |
2013-01-02 |
寿制药株式会社 |
制造光学活性醇的方法
|
US7910698B2
(en)
*
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
WO2007103453A1
(en)
*
|
2006-03-06 |
2007-09-13 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibe compositions
|
WO2008020314A2
(en)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Statin stabilizing dosage formulations
|
US20080032964A1
(en)
*
|
2006-04-10 |
2008-02-07 |
Kansal Vinod K |
Process for the synthesis of azetidinone
|
AR060623A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
Compuestos derivados de 2-azetidinona y un metodo de preparacion
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
RU2009105089A
(ru)
*
|
2006-07-14 |
2010-08-27 |
Ранбакси Лабораториз Лимитед (In) |
ПОЛИМОРФНЫЕ ФОРМЫ ГМГ-КоА-РЕДУКТАЗЫ И ИХ ПРИМЕНЕНИЕ
|
EP1937636A1
(en)
*
|
2006-08-29 |
2008-07-02 |
Teva Pharmaceutical Industries Ltd. |
Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl¨azetidin-2-one
|
WO2008030382A1
(en)
*
|
2006-09-05 |
2008-03-13 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
CN101528746A
(zh)
*
|
2006-09-15 |
2009-09-09 |
先灵公司 |
治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
|
EP2091534A1
(en)
*
|
2006-09-15 |
2009-08-26 |
Schering Corporation |
Azetidinone derivatives and methods of use thereof
|
EP2061796A2
(en)
|
2006-09-15 |
2009-05-27 |
Schering Corporation |
Azetidine and azetidinone derivatives useful in treating pain and disorders of lipid metabolism
|
WO2008033464A2
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidinone derivatives for the treatment of disorders of the lipid metabolism
|
CN101541795A
(zh)
*
|
2006-09-15 |
2009-09-23 |
先灵公司 |
用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
WO2008085300A1
(en)
*
|
2006-12-20 |
2008-07-17 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compounds
|
AU2007338625A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Aegerion Pharmaceuticals, Inc. |
Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
|
EP1939174A1
(en)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
|
EP2125715A2
(en)
*
|
2007-01-24 |
2009-12-02 |
Krka |
Process for the preparation of ezetimibe and derivatives thereof
|
WO2008096372A2
(en)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Process for preparing highly pure ezetimibe using novel intermediates
|
WO2008104875A1
(en)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones as cholesterol absorption inhibitors
|
EP2133347A4
(en)
|
2007-03-06 |
2010-03-17 |
Teijin Pharma Ltd |
1-BIARYLAZETIDINONDERIVATE
|
WO2008112166A2
(en)
|
2007-03-09 |
2008-09-18 |
Indigene Pharmaceuticals Inc. |
Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
|
WO2008123953A1
(en)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Anti-hypercholesterolemic compound
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
WO2009005646A2
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
WO2009005671A2
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
AU2008281640A1
(en)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Pharmaceutical compositions and process for making them
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
WO2009027785A2
(en)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
1, 3-oxazole derivatives as cetp inhibitors
|
US20090093627A1
(en)
*
|
2007-08-30 |
2009-04-09 |
Lorand Szabo |
Process for preparing intermediates of ezetimibe by microbial reduction
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
UA103179C2
(uk)
|
2007-12-10 |
2013-09-25 |
Ратиофарм Гмбх |
Фармацевтична композиція, що містить езетиміб
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(en)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetimibe process and composition
|
CA2724873A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Nicox S.A. |
Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
EP2329014B1
(en)
|
2008-08-29 |
2014-10-22 |
Codexis, Inc. |
Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
|
AU2009315314B2
(en)
|
2008-11-14 |
2013-04-18 |
Bomi P. Framroze |
A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
|
EP2204170A1
(en)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Pharmaceutical composition comprising ezetimibe and simvastatin
|
EP2379547A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2379562A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
EP2216016A1
(en)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Process for the preparation of a pharmaceutical composition comprising ezetimibe
|
CA2754384A1
(en)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Pharmaceutical hypocholesterolemic compositions
|
EP2229938B9
(en)
|
2009-03-13 |
2012-04-25 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Ezetimibe compositions
|
US9040688B2
(en)
|
2009-03-31 |
2015-05-26 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
US9388440B2
(en)
|
2009-04-01 |
2016-07-12 |
Mylan Laboratories Limited |
Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
|
WO2011002424A2
(en)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Solubility and stability enchancing pharmaceutical formulation
|
WO2011019326A2
(en)
|
2009-07-02 |
2011-02-17 |
Mahmut Bilgic |
Solubility and stability enchancing pharmaceutical formulation
|
EP2448564A2
(en)
|
2009-07-02 |
2012-05-09 |
Bilgic Mahmut |
Solubility enhancing pharmaceutical formulation
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
ES2575560T3
(es)
|
2009-08-19 |
2016-06-29 |
Codexis, Inc. |
Polipéptidos cetorreductasa para preparar fenilefrina
|
DE112011100657T5
(de)
|
2010-02-24 |
2013-02-28 |
Relypsa, Inc. |
Amin-polymere zur verwendung als gallensäuresequestriermittel
|
WO2011106542A2
(en)
|
2010-02-24 |
2011-09-01 |
Relypsa, Inc. |
Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants
|
CN106478948B
(zh)
|
2010-02-24 |
2019-05-07 |
瑞立普萨公司 |
用作胆汁酸螯合剂的聚咪唑
|
EP2368543A1
(en)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
|
SI2561069T1
(sl)
|
2010-04-23 |
2017-07-31 |
Alexion Pharmaceuticals, Inc. |
Encim za bolezen lizosomskega shranjevanja
|
WO2011140219A1
(en)
|
2010-05-04 |
2011-11-10 |
Codexis, Inc. |
Biocatalysts for ezetimibe synthesis
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
SG10201507199UA
(en)
|
2010-09-09 |
2015-10-29 |
Synageva Biopharma Corp |
Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
|
RU2619215C2
(ru)
|
2010-11-08 |
2017-05-12 |
Альбирео Аб |
Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
|
EP2637668B1
(en)
|
2010-11-08 |
2016-05-11 |
Albireo AB |
Ibat inhibitors for the treatment of liver diseases
|
WO2012076030A1
(en)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
KR20140006037A
(ko)
|
2011-02-15 |
2014-01-15 |
시나게바 바이오파르마, 코포레이션 |
리소좀의 산 리파제 결핍을 치료하는 방법들
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
WO2013166117A1
(en)
|
2012-05-01 |
2013-11-07 |
Althera Life Sciences, Llc |
Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
US9649294B2
(en)
|
2013-11-04 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
WO2015092448A1
(en)
|
2013-12-18 |
2015-06-25 |
Rudjer Boskovic Institute |
Beta-lactam cholesterol absorption inhibitors
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
MX2016015467A
(es)
|
2014-05-30 |
2017-03-23 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
|
CN105294426B
(zh)
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
MX2017011499A
(es)
|
2015-03-13 |
2018-03-26 |
Esperion Therapeutics Inc |
Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
EP3549040A4
(en)
|
2016-12-05 |
2020-06-24 |
Patsnap Limited |
SYSTEMS, APPARATUSES AND METHODS FOR SEARCHING AND DISPLAYING INFORMATION AVAILABLE IN LARGE DATABASES ACCORDING TO THE SIMILARITY OF CHEMICAL STRUCTURES DISCUSSED THEREIN
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(en)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Pharmaceutical composition comprising ezetimibe
|
US11408274B2
(en)
|
2018-01-16 |
2022-08-09 |
Q.E.D. Environmental Systems, Inc. |
Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
|
JP2022525545A
(ja)
|
2019-03-20 |
2022-05-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ステロール調節エレメント結合転写因子1(srebf1)阻害剤による上昇した脂質レベルの治療
|
EP3942047A1
(en)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
|
BR112022001783A2
(pt)
|
2019-07-31 |
2022-03-22 |
Tecnimede Soc Tecnico Medicinal Sa |
Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
|
EP4188338A1
(en)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Bilayer tablet comprising ezetimibe and atorvastatin
|
JP2024523040A
(ja)
*
|
2021-06-17 |
2024-06-25 |
浙江海正薬業股▲ふん▼有限公司 |
ハイブチミブ中間体およびその調製法
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2024151311A1
(en)
|
2023-01-09 |
2024-07-18 |
Esperion Therapeutics, Inc. |
Methods of treatment using bempedoic acid
|